Search

Asimadoline

It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases. … Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.

Rivoglitazone

Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

VAD-044

VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

Mycobacterium w. Vaccine

As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii.

Lunacalcipol

This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways.

Dibekacin

Dibekacin is an aminoglycoside antibiotic marketed in Japan .

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

Mavelertinib

Mavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).

Petrelintide

Petrelintide is under investigation in clinical trial NCT06662539 (Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities).

Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen